# Neion Bio

> Neion Bio is a New York biotech company that genetically engineers chicken eggs into factories for complex biologic drugs. Its Raptor platform aims to make monoclonal antibodies and other glycosylated proteins at a fraction of the capital cost and carbon footprint of conventional cell-culture bioreactors. Founded in 2024 and emerged from stealth in March 2026, the company raised an oversubscribed $23 million Series A in June 2026 and signed an early multi-product biosimilar deal with a major global pharmaceutical company.

- **Founded:** 2024
- **Headquarters:** New York, New York, United States
- **Founders:** Demetrios (Dimi) Kellari (Co-Founder & CEO), Dr. Sam Levin (Co-Founder & CTO)
- **Team size:** ~14 employees
- **Products:** Raptor Platform, Biosimilars, Innovative Medicines, Critical Reagents, Animal Health Products
- **Notable:** Emerged from stealth in March 2026 with a signed multi-product biosimilar partnership already in place, Raised an oversubscribed $23 million Series A in June 2026, Developed the Raptor platform to produce complex glycosylated proteins in eggs

## Products & services

- **Raptor Platform** — Proprietary genetic-engineering platform that restricts recombinant protein production to the chicken egg, turning eggs into bioreactors for complex, glycosylated proteins such as monoclonal antibodies. Neion claims it lowers capital expenditure by up to 100x and reduces manufacturing carbon footprint by 10-100x compared with conventional cell culture.
- **Biosimilars** — Lower-cost versions of complex biologic drugs, including monoclonal antibodies, produced via the Raptor platform - the focus of Neion's first commercial pharmaceutical partnership.
- **Innovative Medicines** — Novel therapeutic proteins developed on the egg-based manufacturing platform.
- **Critical Reagents** — Research and industrial proteins and reagents produced at lower cost and with resilient supply.
- **Animal Health Products** — Biologics and proteins for the veterinary and animal-health market.

## Achievements

- Emerged from stealth in March 2026 with a signed multi-product biosimilar partnership already in place
- Raised an oversubscribed $23 million Series A in June 2026
- Developed the Raptor platform to produce complex glycosylated proteins in eggs
- Featured in The New York Times by science writer Carl Zimmer
- Assembled a leadership team spanning aerospace engineering, avian science, and commercial pharma

## Latest updates

- **2026-06** — Closed an oversubscribed $23 million Series A led by Caffeinated Capital, with new investors Digitalis Ventures, Ensemble VC and Trust Ventures, to advance the platform and expand the product pipeline.
- **2026-03** — Emerged from stealth with roughly $11 million in early financing and a multi-product biosimilar partnership with a major global pharmaceutical company.

## Links

- Website: https://neionbio.com
- LinkedIn: https://www.linkedin.com/company/neion-bio-inc

---

Profile page: https://yespress.io/neion-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-18